• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23488 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ivacaftor - Assessment according to § 35a (1), Sentence 10, Social Code Book V (dossier assessment)]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [IV immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss]
2010     Andalusian Health Technology Assessment Area (AETSA) [Isolated limb perfusion for locally advanced melanoma and soft tissue sarcoma]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isoflurane (sedation of mechanically ventilated patients) - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isoflavone: Evidence report for the S3 guideline on peri- and postmenopause - diagnostics and interventions]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isavuconazole - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Benefit assessment according to §35a Social Code Book V - Addendum]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Isatuximab (multiple myeloma after >= 1 prior therapy, combination with carfilzomib und dexamethasone) - Benefit assessment according to §35a Social Code Book V - Addendum]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Is top-level care for ovarian cancer patients more cost-effective than regular care?]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Is there a place for home oxygen therapy in the management of obstructive sleep apnea?]
2022     HTA South [Is there a difference in outcome between closing the palate in one or two stages?]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Irreversible electroporation in pancreatic cancer]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Irreversible electroporation in pancreatic and liver cancer]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irreversible electroporation in chronic bronchitis - Addendum to commission H20-03]
2019     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Irreversible electroporation for the treatment of liver and pancreatic cancer]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Irreversible electroporation for renal cancer]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irreversible electroporation for chronic bronchitis - Assessment according to §137h Social Code Book V]
2025     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Irradiation of the skin with intense pulsed light and radiofrequency for stage I and II hidradenitis suppurativa (Hurley Score)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria); assessment according to §35a Social Code Book V; search for disease registries]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria); assessment according to §35a Social Code Book (SGB) V; estimation of patient numbers]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Iptacopan (paroxysmal nocturnal haemoglobinuria with haemolytic anaemia) – Assessment according to §35a SGB V (1), Sentence 11]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Ipilimumab for patients with metastatic melanoma]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (NSCLC) - Addendum to Commission A20-116]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (non-small cell lung cancer, combination with nivolumab) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab (melanoma) - Benefit assessment according to §35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ipilimumab - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2010     Committee for New Health Technology Assessment (CNHTA) [IORT technique using x-ray]
2024     Institute for Clinical Effectiveness and Health Policy (IECS) [Iontophoresis for primary palmar and plantar hyperhidrosis]
2016     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Iontophoresis assisted corneal crosslinking]
1995     Basque Office for Health Technology Assessment (OSTEBA) [Iodinated contrast media in radiodiagnosis]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Involvement of citizens and patients in HTA-processes – international experiences and good practice examples]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and fact sheet for breast cancer Screening - Rapid report]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and decision guide for breast cancer screening]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and decision aid for cervical cancer screening]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Invitation and decision aid for bowel cancer screening]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Investigation, treatment and monitoring algorithms for prostate cancer]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Investigation of the statistical properties of methods for the applicability of study results to subpopulations]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Investigating the added value of conjoint analysis for the evaluation of barriers and facilitators in implementation studies: the case of breast cancer surgery in ultra-short stay]
2012     Andalusian Health Technology Assessment Area (AETSA) [Invasive telemonitoring in patients with heart failure]
2023     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Invasive monitoring of pulmonary artery pressure in patients with symptomatic heart failure]
2010     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Invasive home mechanical ventilation, mainly focused on neuromuscular disorders]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Invasive electroencephalography monitoring with depth electrodes in presurgical assessment of patients with refractory epilepsy]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Invasive electroencephalography for drug-resistant epilepsy]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Introduction to mini-HTA: a management and decision support tool for the hospital service]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Introduction to mini-HTA to municipalities]
2007     Center for Medical Technology Assessment (CMT) [Introduction of care programs within child- and adolescent psychiatry in the county of Ostergotland, Sweden]
2005     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Introduction of advanced care to pre-hospital services in Quebec]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Introduction of a breast cancer care programme in ultra short stay (ambulatory/24 hour stay setting) in 4 early adopter centres: implementation and evaluation]
2017     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intravitreal injections. Effectiveness and safety based on the place of the procedure]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Intravesical hyaluronic acid in interstitial cystitis/painful bladder syndrome]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Intravesical hyaluronic acid for painful bladder syndrome / interstitial cystitis]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Intravenous thrombolytic treatment after acute stroke and secondary antithrombotic prevention treatment (antiplatelet and anticoagulant treatment) after stroke]
2022     Norwegian Institute of Public Health (NIPH) [Intravenous ketamine for treatment-resistant depression and suicidal ideation: a single technology assessment - mapping]
2021     Norwegian Institute of Public Health (NIPH) [Intravenous immunoglobulin treatment in children with PANS/PANDAS conditions]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intravascular ultrasound in coronary artery disease]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Intravascular brachytherapy for peripheral vascular disease]
2008     Committee for New Health Technology Assessment (CNHTA) [Intrathecal, intravascular or epidural drug infusion pump implantation][CRD COPY]
2008     Committee for New Health Technology Assessment (CNHTA) [Intrathecal, intravascular or epidural drug infusion pump implantation]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Intrathecal opioid infusion pump for chronic cancer and non-cancer pain]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intrathecal baclofen pump in spastic patients]
2009     Committee for New Health Technology Assessment (CNHTA) [Intrastromal corneal ring surgery]
2015     Institut national d'excellence en sante et en services sociaux (INESSS) [Intraoperative ultrasound-guided breast-conserving surgery]
2011     Committee for New Health Technology Assessment (CNHTA) [Intraoperative Radiotherapy with Low Energy X-rays]
2008     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative radiotherapy in soft tissues sarcomas]
2023     Canary Health Service [Intraoperative radiotherapy in resectable brain tumors and metastases]
2007     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative radiotherapy in pancreatic cancer]
2014     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative radiotherapy in colorectal cancer]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative radiotherapy in breast and colorectal cancer]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Intraoperative radiotherapy for primary breast cancer]
2013     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative radiation therapy in the treatment of breast cancer]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative Radiation Therapy for Breast Cancer]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Intraoperative Radiation Therapy for Breast Cancer]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Intraoperative magnetic resonance imaging in neurosurgery]
2024     National Evidence-based Healthcare Collaborating Agency (NECA) [Intraoperative CT imaging system for navigational spine surgery]
2010     Committee for New Health Technology Assessment (CNHTA) [Intraoperative computed tomography for neuronavigation in neurological surgery]
2018     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Intraoperative cholangiography in cholecystectomy]
2006     Canary Health Service [Intraoperative ablation of atrial fibrillation]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intranasal esketamine for severe resistant major depression]
2009     Committee for New Health Technology Assessment (CNHTA) [Intramuscular transplantation of autologous bone marrow stem cell(therapeutic angiogenesis)]
2010     Committee for New Health Technology Assessment (CNHTA) [Intralase Femtosecond (FS) laser for corneal surgery]
2006     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Intragastric balloon for treating obesity]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Intradiscal electrocoagulation therapy (IDET) for chronic back pain]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Intradialytic parenteral nutrition in patients with chronic kidney conditions]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Intracorneal rings for patients with keratoconus]
2008     Committee for New Health Technology Assessment (CNHTA) [Intraarticular PCA(Patient Controlled Analgesia)]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Intra-articular use of hyaluronic acid in the treatment of knee osteoarthritis]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Intra-articular injection of platelet-rich plasma for treating knee arthrosis]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Intra-articular hyaluronic acid (viscosupplementation) in osteoarthritis]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Intra-articular hyaluronic acid (viscosupplementation) for osteoarthritis]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Intra-arterial chemotherapy for retinoblastoma]
2009     Committee for New Health Technology Assessment (CNHTA) [Intra-abdominal pressure monitoring with abviser]
2015     The Swedish Council on Health Technology Assessment (SBU) [Interventions to prevent misuse of alcohol, drugs and gambling in youth]
2015     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Interventions to improve health-related behaviours of men]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Interventions to improve foster children’s mental and physical health]